{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:35:22Z","timestamp":1794465322386,"version":"4.9.1"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:sec id=\"ab-hbr230028-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Elevated lipoprotein(a) (Lp[a]) is a putative causal risk factor for atherosclerotic cardiovascular disease (ASCVD). There are conflicting data as to whether Lp(a) may increase cardiovascular risk only in the presence of concomitant inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr230028-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate whether Lp(a) is associated with cardiovascular risk independent of high-sensitivity C-reactive protein (hs-CRP) in both primary and secondary prevention populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr230028-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cohort study uses data from 3 distinct cohorts, 1 population-based cohort and 2 randomized clinical trials. Participants included individuals from the UK Biobank (data from 2006-2010) without prevalent ASCVD, participants in the FOURIER (TIMI 59) trial (data from 2013-2017) who had baseline Lp(a) and hs-CRP data, and participants in the SAVOR-TIMI 53 trial (data from 2010-2013) who had prevalent ASCVD and baseline values for Lp(a) and hs-CRP. The data analysis took place from November 2022 to November 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr230028-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Baseline plasma Lp(a), considered either as a continuous variable or dichotomized at 125 nmol\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr230028-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Risk of major adverse cardiovascular events (MACE) (composite of cardiovascular death, myocardial infarction [MI], or ischemic stroke), the individual MACE components, and peripheral artery disease (PAD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr230028-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 357\u202f220 individuals in the UK Biobank without prevalent ASCVD, 232\u202f699 (65%) had low hs-CRP (&amp;amp;lt;2 mg\/L), and 124\u202f521 (35%) had high hs-CRP (\u22652 mg\/L) values. In a Cox proportional hazard model adjusted for ASCVD risk factors, higher Lp(a) was associated with increased cardiovascular risk regardless of baseline hs-CRP value for MACE (hs-CRP \u22652 mg\/L: hazard ratio [HR] per 50-nmol\/L higher Lp[a], 1.05; 95% CI, 1.04-1.07;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001; for hs-CRP &amp;amp;lt;2 mg\/L: HR, 1.05; 95% CI, 1.04-1.07;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.80 for interaction), as well as MI, ischemic stroke, and PAD individually. Among 34\u202f020 individuals in the FOURIER and SAVOR trials with baseline cardiometabolic disease, there were 17\u202f643 (52%) with low and 16\u202f377 (48%) with high baseline hs-CRP values. In Cox proportional hazard models using aggregated data from FOURIER and SAVOR, higher baseline Lp(a) was associated with increased cardiovascular risk regardless of baseline hs-CRP for MACE (hs-CRP \u22652 mg\/L: HR per 50-nmol\/L higher Lp[a], 1.02; 95% CI, 1.00-1.05;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.04; hs-CRP &amp;amp;lt;2 mg\/L: HR, 1.05; 95% CI, 1.02-1.08;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.16 for interaction), MI, and PAD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr230028-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this study, higher levels of Lp(a) were associated with MACE, MI, and PAD in both primary and secondary prevention populations regardless of baseline hs-CRP value.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2023.5605","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T11:01:43Z","timestamp":1707908503000},"page":"385","source":"Crossref","is-referenced-by-count":135,"title":["Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations"],"prefix":"10.1001","volume":"9","author":[{"given":"Aeron M.","family":"Small","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston"},{"name":"Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Pournamdari","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Department of Biomedical Data Science, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio E.M.","family":"Melloni","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Scirica","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itamar","family":"Raz","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hadassah Hebrew University Hospital, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina M.","family":"Peloso","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Marston","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Natarajan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Associate Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"hbr230028r1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis.","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"hbr230028r2","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review.","volume":"7","author":"Duarte Lau","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"20","key":"hbr230028r3","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease.","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"hbr230028r4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease.","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"hbr230028r5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"hbr230028r6","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction.","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"hbr230028r7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a): Multi-Ethnic Study of Atherosclerosis.","volume":"78","author":"Zhang","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"hbr230028r8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1001\/jamacardio.2020.2413","article-title":"Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE Trial.","volume":"5","author":"Puri","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"18","key":"hbr230028r9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"hbr230028r10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"hbr230028r11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jacl.2022.10.004","article-title":"Lipoprotein(a) and inflammation: pathophysiological links and clinical implications for cardiovascular disease.","volume":"17","author":"Simantiris","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"2","key":"hbr230028r12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jacl.2017.12.004","article-title":"Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: the Ioannina Study.","volume":"12","author":"Naka","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"16","key":"hbr230028r13","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/eurheartj\/ehad055","article-title":"Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein.","volume":"44","author":"Thomas","year":"2023","journal-title":"Eur Heart J"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2814836\/jamacardiology_small_2024_br_230028_1711658483.14768.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T11:01:39Z","timestamp":1712746899000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2814836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.5605","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}